What Fueled The Previous Growth In The Pericarditis Market?
The pericarditis market has seen considerable growth due to a variety of factors.
• The market size of pericarditis has seen robust growth in the past few years. Its size will increase from $2.32 billion in 2024 to $2.51 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.2%. The surge in growth during the historic timeframe is as a result of factors such as a higher incidence of cardiovascular diseases, an aging population with increased disease risks, enhanced grasp of disease pathophysiology, the globalization of healthcare, and advancements and innovation in drug development.
What Is The Expected Growth In The Pericarditis Market Size In The Coming Years?
The Pericarditis market is expected to maintain its strong growth trajectory in upcoming years.
• In the forthcoming years, the market size of pericarditis is predicted to witness a profound surge. By 2029, the industry will reach a valuation of $3.45 billion growing at a compound annual growth rate (CAGR) of 8.2%.
Factors contributing to such growth during this time frame include the rising emphasis on precision medicine, regulatory assistance for rare drugs, patient advocacy groups, increased research on inflammatory pathways, and worldwide cardiovascular disease prevention initiatives. Key trends for the same period include improvements in diagnostic technologies, the implementation of artificial intelligence in diagnostics, managing recurrent pericarditis, telemedicine's role in subsequent care, patient education and support, as well as advancements in imaging technologies.
What Main Forces Are Fueling Expansion In The Pericarditis Market?
A surge in cardiovascular disease cases is poised to drive growth in the pericarditis market. Cardiovascular illnesses encompass a range of health conditions affecting the heart and blood vessels, which are often related to fatty deposit buildup within arteries and higher risk of blood clot formation. Untreated pericarditis may lead to cardiovascular diseases or even fatal outcomes in severe scenarios, which is why the mounting incidences of cardiovascular diseases are spurring the market. For instance, as per a report by the US-based national public health agency, the Centers for Disease Control and Prevention, in October 2022, a heart attack strikes every 40 seconds in the US with approximately 805,000 Americans suffering a heart attack annually. One fifth of these attacks go unnoticed, leaving the victim oblivious to the inflicted damage. Major triggers for heart disease include factors such as smoking, high blood pressure, and elevated cholesterol levels. Thus, the escalating prevalence of cardiovascular diseases is fueling the expansion of the pericarditis devices market.
What Are The Primary Segments In The Global Pericarditis Market?
The pericarditis market covered in this report is segmented –
1) By Type: Acute Pericarditis, Chronic Pericarditis, Recurrent Pericarditis
2) By Diagnosis And Treatment: Electrocardiogram (ECG), Echocardiogram, Computerized Tomography (Ct), X-Ray, Medication, Surgical Treatment
3) By Application: Hospitals And Clinics, Medical Institutes, Ambulatory Surgical Centers, Research Organizations
Subsegments:
1) By Acute Pericarditis: Viral Pericarditis, Bacterial Pericarditis, Idiopathic Pericarditis
2) By Chronic Pericarditis: Constrictive Pericarditis, Non-constrictive Chronic Pericarditis
3) By Recurrent Pericarditis: Post-Acute Pericarditis Recurrences, Secondary Recurrent Pericarditis
Pre-Book The Pericarditis Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Key Trends Are Driving Changes In The Pericarditis Market?
Leading enterprises in the pericarditis market are focusing on creating innovative products such as pericardial tissue valves. This move aims to expand their reach to larger customer segments, drive sales, and boost revenue generation. The valves for pericardial tissues are specifically designed as medical tools for use in heart surgeries, more so in procedures dealing with heart valve repair or replacement. As a case in point, Edwards Lifesciences, a technological firm based in the US, introduced the SAPIEN 3 Ultra RESILIA valve in September 2022. Having distinct features, the valve integrates the transformative RESILIA tissue technology of Edwards with the industry-leading SAPIEN 3 Ultra transcatheter aortic heart valve. Importantly, RESILIA tissue comprises advanced anti-calcification technology, providing an effective solution to a main aspect leading to the requirement for another intervention post-heart valve replacement. Serving as an exemplary case of Edwards' continuous dedication to innovation, the SAPIEN 3 Ultra RESILIA valve aims to cater to the current and future demands of patients. This pursuit enhances the patients' lifespan, health status, and overall life quality.
Who Are the Key Players In The Pericarditis Market?
Major companies operating in the pericarditis market include:
• Pfizer Inc.
• AstraZeneca plc
• Merck & Co. Inc.
• Novartis International AG
• Johnson & Johnson Services Inc.
• Takeda Pharmaceutical Co. Ltd.
• Zydus Cadila Healthcare Ltd.
• Sun Pharmaceutical Ltd.
• Kiniksa Pharmaceuticals Ltd.
• R-Pharm International LLC
• Regeneron Pharmaceuticals Inc.
• Amgen Inc.
• UCB S.A.
• Daiichi Sankyo Company
• Limited
• Astellas Pharma Inc.
• Biogen Inc.
• Gilead Sciences
• Inc.
• Merck KGaA
• Ipsen S.A.
• and Hikma Pharmaceuticals plc
What Is The Most Dominant Region In The Pericarditis Market?
North America was the largest region in the pericarditis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the pericarditis market report during the forecast period. The regions covered in the pericarditis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
